Robert E. Hoffman - Aug 1, 2022 Form 4 Insider Report for Kintara Therapeutics, Inc. (KTRA)

Role
President and CEO, Director
Signature
/s/ Anthony Scott Praill, attorney-in-fact for Robert E. Hoffman
Stock symbol
KTRA
Transactions as of
Aug 1, 2022
Transactions value $
$0
Form type
4
Date filed
8/3/2022, 04:30 PM
Previous filing
Feb 17, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KTRA Common Stock Award $0 +400K +727.54% $0.00 455K Aug 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTRA Option (right to buy) Award $0 +1.2M $0.00 1.2M Aug 1, 2022 Common Stock 1.2M $0.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.
F2 The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.